Search

Discovering Novel Anti-Angiogenesis & Anti-Metastasis Targets Using Phage Display

Discovering NovelAnti-Angiogenesis & Anti-Metastasis TargetsUsing Phage Display

Creative Biolabs designs phenotype-driven phage display screening programs that connect target or cell-selective enrichment with functional validation. By combining tailored positive/negative selection, endothelial or tumor-cell assays, viability controls, and optional target deconvolution, we help distinguish promising binders from candidates with reproducible effects on angiogenesis- or metastasis-related phenotypes.

Explore Screening Strategy Discuss Your Project

Discovering Novel Anti-Angiogenesis & Anti-Metastasis Targets Using Phage Display

Angiogenesis and metastasis are often grouped together in cancer research, but they are not one phenotype and should not be screened as if a single assay could represent both. Endothelial proliferation, migration, sprouting, and matrix interaction answer vascular questions, while tumor-cell migration, invasion, adhesion, and microenvironmental interactions address different steps in dissemination. Creative Biolabs builds Functional Phage Display Screening programs around the exact biological event you want to change.

We can begin from a defined molecular target, a target-positive cell population, an endothelial state, a tumor-cell phenotype, or an extracellular-matrix context. Phage display is used to generate sequence-defined binders or target hypotheses; functional assays are then selected according to the intended phenotype. This design prevents a common interpretation problem: a clone that binds endothelial or tumor cells can be interesting, but it is not anti-angiogenic or anti-metastatic until an appropriate functional readout demonstrates the effect.

Our service combines positive and negative selection, clone or NGS analysis, matched viability measurements, and orthogonal functional testing. We can also connect cell-selected or matrix-selected ligands to receptor-deconvolution studies when the molecular target is unknown. The result is a staged discovery program in which binding, phenotype, and mechanism are clearly separated and each experiment answers a defined next question.

Fig.1 A diagram illustrating the process of tumor angiogenesis, showing how a tumor microenvironment triggers abnormal blood vessel growth that ultimately promotes cancer growth and metastasis. (OA Literature)
Fig.1 The role of tumor angiogenesis in cancer growth and metastasis.1

Two Discovery Routes with Different Biological Endpoints

Angiogenesis, metastasis, and extracellular-matrix discovery routes
Route Typical Research Question Useful Functional Readouts
Endothelial / angiogenesis-related Does a selected candidate alter endothelial proliferation, migration, matrix interaction, or morphogenesis in the chosen model? Cell proliferation, migration, tube formation, spheroid sprouting, adhesion, and target-dependent signaling.
Tumor migration / metastasis-related Does a candidate alter tumor-cell motility, invasion through matrix, adhesion, or a defined microenvironmental interaction? Wound/collective migration, Transwell migration, matrix-coated invasion, adhesion, and pathway-specific secondary assays.
ECM-focused discovery Does the candidate recognize or perturb an extracellular-matrix feature involved in the phenotype? Direct/competitive matrix binding followed by cell adhesion, spreading, migration, or receptor-deconvolution assays.

The routes can be connected, but we do not force them into one universal workflow. A vascular-homing peptide may be prioritized for endothelial selectivity without directly affecting morphogenesis. A tumor-cell ligand may reduce invasion while leaving migration on an uncoated surface unchanged. A matrix-binding candidate can influence adhesion or receptor availability without acting directly on a cell-surface receptor. Defining these distinctions at the start makes the final candidate set much easier to interpret.

Select the Cell and Matrix Context Deliberately

The most familiar model is not always the most informative. We select endothelial, tumor-cell, and matrix contexts based on target expression, vascular or tumor subtype, disease context, relevant signaling state, and the availability of matched negative controls. HUVECs can be useful, but they are not treated as the default for every vascular question.

Intact-cell screening is preferred when native membrane topology, glycans, receptor density, or other surface features matter. Matched target-negative cells and related matrix controls help determine whether enrichment follows the intended biology, while ECM-focused selection can be used when matrix recognition is central to the phenotype. For downstream functional assays, matrix composition, coating, cell density, and timing are documented because they can alter tube formation, migration, and invasion; key effects can be confirmed in an orthogonal assay or additional model.

Our Angiogenesis and Metastasis Screening Workflow

  1. 01

    Define Phenotype & Models

    Define the endothelial, migration, invasion, adhesion, or ECM endpoint and select interpretable positive and negative materials.

  2. 02

    Select & Deplete

    Enrich the phage library on the intended surface while depleting binders to related cells, matrix, tags, carriers, and background components.

  3. 03

    Sequence & Reconfirm

    Use clone sequencing or NGS to identify enriched families, then reconfirm candidate binding against the intended surface and counters.

  4. 04

    Test Functional Activity

    Evaluate prioritized candidates in the relevant phenotype assay with matched viability, proliferation, cell-count, and reference controls.

  5. 05

    Confirm Orthogonally

    Repeat decisive effects in another assay, model, or non-phage format before target deconvolution or mechanism studies.

Prevent Cell Loss from Looking Like Anti-Migration or Anti-Angiogenic Activity

Migration, invasion, tube formation, and sprouting can all be confounded by cytotoxicity, reduced proliferation, or model-specific effects. We therefore pair phenotype assays with viable cell number or proliferation controls at biologically appropriate time points and interpret in vitro morphogenesis only as evidence for the behavior measured, not as direct proof of in vivo anti-angiogenic activity.

Functional readouts, controls, and interpretation boundaries
Question Example Readout Essential Control Interpretation Boundary
Endothelial proliferation Cell count or proliferation assay Viability and vehicle/reference control Not equivalent to vessel formation.
Endothelial morphogenesis Tube formation or spheroid sprouting Matrix, timing, viability, and benchmark control In vitro model of selected vascular behavior.
Tumor migration Wound or Transwell migration Proliferation and viability Reduced cell number can mimic inhibition.
Tumor invasion Matrix-coated Transwell or related 3D barrier Matrix and viability controls Model dependent and distinct from migration.
ECM recognition Direct or competition binding Related-matrix specificity panel Binding alone does not establish cell function.

Target Deconvolution When the Molecular Receptor Is Unknown

Phenotype-first or intact-cell phage selection can generate useful ligands before the receptor is known. If target identification is part of the program, we plan enough candidate material and the right negative controls for follow-up. Competition with soluble proteins, affinity capture, binding to recombinant candidates, receptor-expression perturbation, and interaction-mapping approaches can all contribute, depending on the system.

We do not assign a receptor from sequence similarity or from cell binding alone. A selected peptide may recognize a matrix-associated feature or a multicomponent surface. The target-deconvolution strategy is therefore chosen after the binding phenotype is reproducible and is connected to the biological question you ultimately want to answer.

Project Inputs and Deliverables

You do not need to have every parameter finalized before contacting us. A useful starting point is the biological question and the model or material you plan to screen; our team can help define the most informative controls, assay route, and level of follow-up.

Project Inputs

What to Share

  • Target or cell model
  • Endothelial/tumor state or ECM context
  • Desired phenotype or functional readout
  • Positive and negative materials
  • Reference control, if available
  • Library format and selectivity requirements
  • Whether the molecular target is known
Project Outputs

What You May Receive

  • Enriched phage pools and sequence families
  • Clone-level binding data
  • Cell/matrix specificity comparisons
  • Endothelial proliferation or morphogenesis data
  • Migration or invasion results
  • Non-phage confirmation and prioritized candidates
  • Target-deconvolution recommendations, when relevant

Outputs are reported according to the model and assay performed, with binding, functional phenotype, and later target or mechanism claims kept as separate evidence levels.

Published Data

CAM assay showing reduced neovascularization after treatment with the phage-derived vascular-homing peptide GX1 compared with control peptide and PBS. (OA Literature)
Fig.2 GX1 inhibits angiogenesis in a chorioallantoic membrane assay.2

Chen and colleagues studied the phage-derived peptide GX1 after selection for gastric tumor vasculature. Follow-up work examined binding to endothelial cells and evaluated effects on endothelial proliferation and apoptosis as well as neovascularization in a chorioallantoic-membrane model. The study is a useful example of moving from a vascular-homing selection signal to independent functional experiments rather than assigning anti-angiogenic activity from phage enrichment alone. For Creative Biolabs projects, the relevant lesson is the staged evidence path: selection identifies a candidate, independent binding establishes the preferred biological context, and phenotype-specific assays determine what the candidate actually changes. The design can then be extended to receptor identification or mechanism only when those data are needed.

Discuss Your Angiogenesis or Metastasis Project

If your program focuses on endothelial behavior, tumor migration or invasion, ECM interactions, or a related phenotype, send us your model, positive and negative materials, library format, functional readout, viability controls, and target-identification needs. Creative Biolabs can help you build a research-use phage display strategy that connects selection to the right functional evidence.

Discuss Your Project

What to Share

Target or cell model
Desired phenotype or functional readout
Library format and selectivity requirements
Whether the molecular target is known

Great Partners with Creative Biolabs

Frequently Asked Questions

Does inhibition of tube formation prove anti-angiogenic activity in vivo?
No. Tube formation is an in vitro morphogenesis assay that captures selected aspects of endothelial organization under a particular matrix, density, and timing condition. It does not reproduce blood flow, immune cells, pericytes, stromal interactions, pharmacokinetics, or whole-organism exposure. We use it as one functional readout and strengthen interpretation with complementary assays when needed.
How do you separate migration inhibition from cytotoxicity?
We measure viability, cell number, or proliferation alongside the migration or invasion assay and choose time points that help establish the order of events. If cell loss precedes the apparent migration effect, the result is interpreted differently from a motility change that occurs while viable cell number remains stable. Orthogonal migration formats can provide additional confidence.
Which endothelial cell model should be used for an angiogenesis project?
The model should reflect the biological target, species, vascular bed, disease context, and available controls. HUVECs are widely used but are not universally representative of every endothelial phenotype. We review target expression, culture conditions, matrix environment, and the intended endpoint before selecting a model, and we can incorporate an additional endothelial background when specificity is important.
Can phage display discover a ligand without a known receptor?
Yes. Intact-cell or matrix-focused selection can enrich ligands against a biological surface without requiring a predefined molecular target. The immediate output is a cell- or matrix-selective candidate. If receptor identity is needed later, we can plan a separate deconvolution strategy using competition, affinity capture, recombinant proteins, expression perturbation, or other suitable approaches.
Is invasion the same as migration in a functional screen?
No. Migration measures cell movement, whereas invasion adds passage through a matrix or barrier and can depend on adhesion, matrix remodeling, protease activity, and other factors. A candidate may reduce invasion without directly reducing motility. We therefore choose the assay according to the biological step of interest and avoid using the two terms interchangeably.
Should selected candidates be tested outside the phage format?
Yes when the downstream molecule is a free peptide, soluble antibody fragment, IgG, or another reformatted construct. Phage multivalency and particle geometry can increase avidity or influence cell-surface behavior. Repeating the decisive binding and phenotype experiments in the intended molecular format helps show that the observed activity belongs to the candidate rather than the display particle.

References

  1. Ayoub, Nehad M., et al. Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Frontiers in Pharmacology 13 (2022): 838133. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fphar.2022.838133
  2. Chen, et al. Functional characterization of the tumor vasculature-homing peptide GX1 and its anti-angiogenic effects. BMC Cell Biology 10 (2009): 63. Distributed under Open Access license CC BY 2.0, without modification. https://doi.org/10.1186/1471-2121-10-63

Please kindly note that our services can only be used to support research purposes (Not for clinical use).

Biophage Technology

Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.

Contact Us
  • Global Locations
Privacy Policy | Cookie Policy | Copyright © 2026 Creative Biolabs. All rights reserved.